Studies illustrating prognostically important geriatric deficits in older patients undergoing alloHCT
| Study . | N . | Age, median (range), y . | Study design disease . | Impairment in GA domains with impact on outcomes . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Comorbidity . | Function . | Mobility . | Cognition . | Medication . | Frailty scale . | ||||
| Muffly et al. (2014)35 | 203 | 58 (54-63) | Prospective, single-center pilot study All diseases | NRM ↑ OS ↓ | NRM ↑ OS ↓ | OS ↓ | |||
| Deschler et al. (2018)36 | 106 | 66 (60-78) | Prospective, single-center trial Myeloid neoplasms | NRM ↑ PFS ↓ | OS ↓ PFS ↓ | OS ↓ | |||
| Huang et al. (2020)37 | 148 | 62 (50-76) | Prospective, single-center pilot study All diseases | OS ↓ PFS ↓ NRM ↑ Toxicities ↑ | |||||
| Pamukcuoglu et al. (2019)40 | 52 | 59 (40-73) | Prospective, single-center pilot study All diseases | OS ↓ Toxicities ↑ | |||||
| Salas et al. (2021)41 | 168 | 58 (19-77) | Prospective, single-center pilot study All diseases | NRM ↑ OS ↓ | NRM ↑ | ||||
| Olin et al. (2020)38 | 330 | 63 (50-77) | Multicenter, CIBMTR registry All diseases | NRM ↑ | NRM ↑ OS ↓ | ||||
| Polverelli et al. (2020)42 | 228 | 64 (60-76) | Two-center retrospective study | NRM ↑ OS ↓ | |||||
| Lin et al. (2020)39 | 457 | 66 (60-79) | Single-center, retrospective study | NRM ↑ | NRM ↑ OS ↓ PFS ↓ | ||||
| Bhargava et al. (2020)43 | 114 | 68 (65-75) | Single-center, retrospective study | Toxicities ↑ OS ↓ | |||||
| Sugidono et al. (2021)44 | 148 | 62 (50-76) | Single-center, retrospective study | OS ↓ | |||||
| Study . | N . | Age, median (range), y . | Study design disease . | Impairment in GA domains with impact on outcomes . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Comorbidity . | Function . | Mobility . | Cognition . | Medication . | Frailty scale . | ||||
| Muffly et al. (2014)35 | 203 | 58 (54-63) | Prospective, single-center pilot study All diseases | NRM ↑ OS ↓ | NRM ↑ OS ↓ | OS ↓ | |||
| Deschler et al. (2018)36 | 106 | 66 (60-78) | Prospective, single-center trial Myeloid neoplasms | NRM ↑ PFS ↓ | OS ↓ PFS ↓ | OS ↓ | |||
| Huang et al. (2020)37 | 148 | 62 (50-76) | Prospective, single-center pilot study All diseases | OS ↓ PFS ↓ NRM ↑ Toxicities ↑ | |||||
| Pamukcuoglu et al. (2019)40 | 52 | 59 (40-73) | Prospective, single-center pilot study All diseases | OS ↓ Toxicities ↑ | |||||
| Salas et al. (2021)41 | 168 | 58 (19-77) | Prospective, single-center pilot study All diseases | NRM ↑ OS ↓ | NRM ↑ | ||||
| Olin et al. (2020)38 | 330 | 63 (50-77) | Multicenter, CIBMTR registry All diseases | NRM ↑ | NRM ↑ OS ↓ | ||||
| Polverelli et al. (2020)42 | 228 | 64 (60-76) | Two-center retrospective study | NRM ↑ OS ↓ | |||||
| Lin et al. (2020)39 | 457 | 66 (60-79) | Single-center, retrospective study | NRM ↑ | NRM ↑ OS ↓ PFS ↓ | ||||
| Bhargava et al. (2020)43 | 114 | 68 (65-75) | Single-center, retrospective study | Toxicities ↑ OS ↓ | |||||
| Sugidono et al. (2021)44 | 148 | 62 (50-76) | Single-center, retrospective study | OS ↓ | |||||
NRM, nonrelapse mortality; PFS, progression-free survival.